Contraindicated in:
Use Cautiously in:
Drug-Drug:
Therapeutic Classification: agents for amyotrophic lateral sclerosis, n/a
Pharmacologic Classification: histone deacetylase inhibitors, bile acid replacements
Absorption: Extent of absorption following oral administration unknown. High-fat meal decreases absorption of sodium phenylbutyrate.
Distribution: Unknown.
Protein Binding: Sodium phenylbutyrate: 82%; Taurursodiol: 98%.
Metabolism/Excretion: Sodium phenylbutyrate is metabolized in the liver and kidney. Taurursodiol undergoes enterohepatic recirculation. Sodium phenylbutyrate primarily (80100%) excreted in urine as a metabolite. Excretion pathway of taurursodiol unknown.
Half-life: Sodium phenylbutyrate: 0.46 hr; Taurursodiol: 4.3 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Sodium phenylbutyrate (PO) | unknown | 30 min | unknown |
Taurursodiol (PO) | unknown | 4.5 hr | unknown |